This is a numbers-first look at Suven Life Sciences Limited (SUVEN), covering income trends, margins, valuation, and shareholding.
Suven Life Revenue Trend
Top-line pressure showed for Suven Life Sciences Limited, with revenue declining 43.1% to ₹6.66 Cr in FY2025.
The 10-year revenue trajectory tells a worrying story: a 35.3% annual decline from ₹521 Cr to ₹6.66 Cr.
A ₹6.66 Cr revenue base makes Suven Life Sciences Limited a smaller name in the Indian pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹6.66 Cr | -43.1% |
| FY2024 | ₹11.7 Cr | -13.6% |
| FY2023 | ₹13.5 Cr | +14.3% |
| FY2022 | ₹11.8 Cr | -44.2% |
| FY2021 | ₹21.2 Cr | — |
View Suven Life Sciences Limited's full 10-year revenue trend with CAGR analysis →
Suven Life Profitability
Per-share earnings moved to ₹-7.37 in FY2025 from ₹-4.82 in FY2024.
Is Suven Life Undervalued
Suven Life Sciences Limited shares are currently trading at ₹307.20.
Craytheon calculates intrinsic value using the P/E Ratio and EPS Growth models. Both appear in the Valuation Models cards below.
Valuation Models
Suven Life Shareholding Pattern
At 70.1%, the promoter stake is up from 67.4% — a sign of insider confidence.
Foreign institutions moved their stake down to 0.6% from 1.2% over the past year.
On the domestic institutional side, the holding is 2.9% as of June 2026 — down from 3.4%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 70.1% | 0.6% | 2.9% | 26.4% |
| Mar 2026 | 70.2% | 0.9% | 4.6% | 24.3% |
| Dec 2025 | 67.4% | 1.1% | 3.4% | 28.2% |
| Sep 2025 | 67.4% | 1.2% | 3.4% | 28.1% |
Track quarterly shareholding changes for Suven Life Sciences Limited →
Suven Life Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹1.35B at the end of FY2025, down 52.6% from ₹2.85B a year earlier.
Property, Plant & Equipment is the largest block at 44.0%, followed by Cash & ST Investments at 27.6% and Other Assets at 27.1%.
Equity makes up 81.4% of liabilities and equity, with debt at 0.0% and operating liabilities at 18.6%. Notable shift: Other Liabilities is up 65.3% YoY (₹120.84M → ₹199.70M).
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 373.04M |
| Receivables | 13.36M |
| Inventories | 2.38M |
| Property, Plant & Equipment | 594.82M |
| Intangibles & Goodwill | 1.81M |
| Other Assets | 366.43M |
| Category | Value |
|---|---|
| Equity | 1.10B |
| Trade Payables | 52.27M |
| Other Liabilities | 199.70M |
Suven Life Key Highlights
In summary, Suven Life Sciences Limited (SUVEN) presents the following picture for fundamental analysts.
Revenue of ₹6.66 Cr in FY2025, down 43.1% year-over-year.
Long-term revenue has been contracting at 35.3% annually over 10 years.
The company reported a net loss of ₹161 Cr in FY2025.
Unlock Full Analysis
Craytheon's full analysis of Suven Life Sciences Limited goes deeper: three valuation models, growth metrics, and 10 years of financial data.